Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

No extra benefit from long-acting insulin

By News team

Using long-acting insulin for more than six years has no effect on cardiovascular outcomes and cancers, according to a study published online in the New England Journal of Medicine (11 June 2012).

The "outcome reduction with an initial glargine intervention" (ORIGIN) trial included 12,537 patients with cardiovascular risk factors and impaired fasting glucose, impaired glucose tolerance or early type 2 diabetes. Patients were assigned to receive insulin glargine (targeting a self-measured fasting plasma glucose level of 5.3mmol per litre or less) or standard care, which differed depending on diabetes status.

The first co-primary outcome was death from cardiovascular disease, non-fatal myocardial infarction or non-fatal stroke, and the second was a composite of these events plus revascularisation or admission to hospital for heart failure.

After one year, half of patients in the insulin glargine group had reached the fasting plasma glucose target level, which was maintained over six years.

The incidence of both co-primary outcomes did not differ significantly between treatment groups, with a hazard ratio of 1.02 for co-primary outcome 1 (95 per cent confidence interval 0.94–1.11, P=0.63) and 1.04, for co-primary outcome 2 (CI 0.97–1.11, P=0.27).

Effect of omega-3

Patients in each of the treatment groups (insulin glargine or standard care) were also assigned to receive either 1g omega-3 fatty acids or placebo daily.

Supplementation with omega-3 fatty acids did not reduce cardiovascular disease deaths, which occurred in 9.1% of patients compared with 9.3% of patients receiving placebo (hazard ratio 0.98, 95% confidence interval 0.87–1.10, P=0.72).


Citation: The Pharmaceutical Journal URI: 11103235

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • (Sergii Kolesnyk |

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.